NCT00526045 2020-12-17Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer PatientsNovartisPhase 1/2 Completed117 enrolled
NCT02223052 2020-05-12Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCelgenePhase 1 Completed89 enrolled
NCT02431260 2019-06-14An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated69 enrolled 34 charts